Kunal Taskar

Global Head PBPK Modeling

GSK

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Kunal Taskar is the Global Head of PBPK Modeling at GSK in the United Kingdom. His research focuses on physiologically based pharmacokinetic modeling, with recent articles addressing drug-drug interactions, the effects of various transporters, and the clinical implications of modeling techniques. He has contributed significantly to understanding pharmacokinetics in diverse populations and therapeutic contexts.

Articles (11)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (2)

Konstantinos Stamatopoulos

GlaxoSmithKline (United States)

UNITED KINGDOM

View details

Toshiaki Tsuchitani

Assistant Professor

Keio University Faculty of Pharmacy

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kunal Taskar

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor

Matrix Approach Assessment of Cabotegravir Drug–Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling

Physiologically Based Pharmacokinetic Modeling of Phosphate Prodrugs─Case Studies: Fostemsavir and Fostamatinib

Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective

Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers

Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy

Physiologically‐based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug–drug interactions

Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug

Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective

Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective

Robust PBPK Model of Rifampicin for Predicting Drug‐Drug Interactions via P‐gp Induction and Inhibition in Intestine, Liver, and Kidney

Collaborators (2)

Konstantinos Stamatopoulos

Toshiaki Tsuchitani

Make your next move.